Linzagolix is a synthetic, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist developed for the treatment of hormone-dependent gynecological conditions. It acts directly on GnRH receptors in the pituitary gland and suppresses the secretion of gonadotropins, resulting in reduced production of ovarian sex hormones.
Linzagolix is an orally active small-molecule GnRH antagonist. By reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH), it decreases ovarian estrogen production. This pharmacological mechanism makes linzagolix relevant to the treatment of uterine fibroids and endometriosis-associated symptoms.
Linzagolix is a synthetic small-molecule compound with the molecular formula C22H19F2N5O2 and a molecular weight of approximately 423.43 g/mol. Its CAS Number is 934000-66-9.
The compound is designed for oral administration and belongs to the class of selective GnRH receptor antagonists.
Linzagolix competitively blocks GnRH receptors in the anterior pituitary gland.
GnRH receptor blockade reduces the secretion of LH and FSH. The resulting suppression of ovarian function decreases circulating estrogen levels, which can reduce estrogen-dependent stimulation of uterine tissues.
This mechanism is responsible for its therapeutic effects in hormone-dependent gynecological disorders.
Linzagolix is used in pharmaceutical development and approved clinical applications for the management of moderate-to-severe symptoms associated with uterine fibroids. It has also been investigated and used in the management of endometriosis-associated pain in appropriate regulatory settings.
The approved indications, dosage strengths and combination requirements may vary according to the country and regulatory authority.
Linzagolix API can be evaluated using validated analytical procedures for identification, assay, related substances, water content, residual solvents, elemental impurities and other applicable quality attributes.
Chromatographic and spectroscopic techniques may be used for identity, assay and purity determination. Appropriate control of process-related impurities, degradation products and residual solvents should be included in the applicable drug-substance specification.
Acceptance criteria should be based on the applicable manufacturer's drug-substance specification, Certificate of Analysis and relevant pharmacopoeial and regulatory requirements.
Linzagolix should be stored in a tightly closed pharmaceutical-grade container under controlled conditions. The material should be protected from excessive heat, moisture and direct light.
Specific storage and transportation requirements should follow the applicable manufacturer's approved specification.
Linzagolix API may be supplied for qualified pharmaceutical manufacturing, formulation development, analytical and research applications, subject to applicable quality and regulatory requirements.
Linzagolix API is available for qualified pharmaceutical development and manufacturing requirements subject to applicable quality and regulatory standards. Customers can request product specifications, Certificate of Analysis, analytical documentation, packaging information and commercial details according to their requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 5.0 – 7.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |